title: Molecular response to nilotinib in a patient with imatinib-intolerant e19a2-positive chronic myeloid leukemia.
abstract: The BCR-ABL1 fusion gene is the molecular marker of chronic myeloid leukemia (CML). The e19a2 transcript is a rare variant associated with various clinical presentations and courses of CML. We herein present a case of e19a2-positive CML who was intolerant to initial treatment with imatinib and successfully responded to subsequent nilotinib therapy. She achieved a major molecular response and has since be able to sustain it. According to the literature, achieved molecular response by imatinib monotherapy has not yet been reported in e19a2-positive CML patients. Second generation tyrosine kinase inhibitors may therefore be a more effective treatment for e19a2-positive CML patients.
authors.affiliation: Department of Hematology and Oncology, Tosei General Hospital, Japan.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kajiguchi
authors.forename: Shingo
authors.initials: S
authors.lastname: Okuno
authors.forename: Toshihito
authors.initials: T
authors.lastname: Ohno
authors.forename: Akihiro
authors.initials: A
authors.lastname: Abe
mesh_terms: D001549:Benzamides / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000235:genetics; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000187:drug effects; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib